Company intelligence / Profile preview
Angiotensin Therapeutics Inc.
Evanston, Illinois, United Statesangiotx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has developed a novel soluble ACE2 variant with prolonged duration of action that can neutralize SARS-CoV-2. Their ACE2 variants have been modified to increase duration of action from hours to days, making them more suitable therapeutically. Preclinical studies have shown promise for COVID-19 treatment by intercepting the virus from reaching ACE2 receptors in cell membranes.
- Therapeutic areas
- Infectious DiseasesNephrology
- Modalities
- BiologicsACE2 enzyme variants
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Northwestern University
Beyond the preview
Go deeper on Angiotensin Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiotensin Therapeutics Inc..